Rorze Q2 FY2027: AI Demand Drives Huge Forecast Hike

Explosive semiconductor demand is driving performance. Rorze announced consolidated results for the second quarter of the fiscal year ending February 2027. Sales rose 21.5% year-on-year to 79.733 billion yen, while operating profit jumped 42.4% to 23.1 billion yen. The company also significantly raised its full-year forecast, confirming its solid position and growth potential in the semiconductor manufacturing equipment market.

Sales reached 79,733 million yen, a 21.5% increase from the previous year's actual result of 65,602 million yen. Operating profit was 23,096 million yen (42.4% higher), and ordinary profit reached 24,538 million yen (68.4% higher), benefiting from exchange rates. Profit growth significantly outpaced sales growth, marking a robust "black profit expansion." Net income attributable to parent company shareholders was 15,839 million yen (45.7% higher), maintaining high profitability.

This strong first-half performance stems not merely from economic recovery but from a structural shift driven by the rapid expansion of generative AI demand. Investment in semiconductor manufacturing equipment for data centers is accelerating, leading to order volumes and values hitting record speeds.

The core semiconductor and FDP-related equipment segment saw sales of 79,357 million yen (21.6% increase) and segment profit of 23,969 million yen (43.0% increase). Sales of semiconductor-related equipment were the main driver, with a significant surge in orders from the United States and Taiwan.

Conversely, the LifeScience business saw sales grow only slightly to 376 million yen (2.8% higher), resulting in a segment loss of 147 million yen. While this represents an expansion from the previous year's loss of 119 million yen, its small proportion relative to the rapid growth of the core semiconductor business means it is not hindering overall group growth.

Regionally, sales remain high in the US, with Taiwan, China, and Korea contributing steadily. Particularly in the US market, sales to Applied Materials increased, indicating a dependency ratio of 21.7% and establishing a stable revenue base.

The financial position is very sound. Total assets at the end of the first half of FY2027 reached 218,038 million yen (+20,736 million yen vs prior year actuals), and net assets rose to 155,987 million yen (+16,025 million yen), strengthening the capital base through increased retained earnings. The equity ratio stands at a high 67.2%, with ample working capital.

Cash and deposits increased by 12,036 million yen to 86,378 million yen. While increases in notes receivable and accounts receivable reflect sales growth, reductions in litigation loss reserves also contributed to cash inflow.

Dividend forecasts are set at 28.00 yen for the full year, a significant increase from the previous year's 17.00 yen, reflecting strong mid-term performance and signaling enhanced shareholder returns. No share buyback activity has been reported yet, but future capital policy will likely be scrutinized as retained earnings grow.

Key risks cited include the Middle East situation and natural disasters. The global semiconductor supply chain is fragmented, and geographic disruptions could impact orders and deliveries.

Exchange rate fluctuations also significantly affect ordinary profit. The gap between operating profit growth (42.4%) and ordinary profit growth (68.4%) is largely due to FX effects, making yen appreciation a potential headwind moving forward.

Customer concentration requires attention. Sales to Applied Materials have risen, meaning changes in major clients' capital expenditure plans directly impact results. While Rorze holds niche technology with limited competitors, it relies on tight coordination with Taiwan Semiconductor Manufacturing Company (TSMC) and other manufacturers.

Following its mid-term results, Rorze significantly raised its full-year consolidated forecast for FY2027. This revision magnitude is notable in the industry, highlighting the strength of AI-related semiconductor demand.

Sales are now projected to exceed 180 billion yen, 1.38 times last year's actuals, while operating profit is expected to surpass 53 billion yen, roughly 1.7 times prior levels. Net income is also forecast to nearly double the previous year, reaching approximately 37.8 billion yen, updating the company's all-time record high.

The basis for this revision includes an order backlog of 1 trillion 36.3 billion yen, a 229.8% increase from the prior year. Total orders across LifeScience and other segments also hit records, with expected improvements in capacity utilization and profit margins sustaining through the full year.